Gill Aviation to Help Fund Blood Cancer Research – AviationPros.com

Gill Aviation has initiated a week-long campaign to raise awareness and help fund blood cancer research by donating a portion of fuel sales to the Leukemia & Lymphoma Society (LLS).

From February 3-7, Gill Aviation will donate 5 cents for every gallon of Jet A fuel sold. In addition, donations can be made on-line through a special LLS web page created by Kya Gill, a Houston, Texas high school student, in honor of her sister Paige who underwent treatment for Lymphoma. The goal is to raise $250,000 during the campaign period.

We are very proud of our daughter Kya and her efforts to help fund blood cancer research to fight Leukemia and Lymphoma, two of the most common forms of cancer in children, teens and young adults, said Jag Gill, President of Gill Aviation. We have selected to work with LLS because the research they do provides a gateway to curing these cancers through advanced treatments such as chemotherapy, radiation and stem cell transplantation.

Read the original here:
Gill Aviation to Help Fund Blood Cancer Research - AviationPros.com

Two Day Conference on Cell Therapy Bioprocessing (Boston, MA, United States – June 25-26, 2020) – Gain Insight into the Latest Advancements and…

DUBLIN, Feb. 4, 2020 /PRNewswire/ -- The "2nd Annual Cell Therapy Bioprocessing Conference" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. There are factors like manufacturing maze, investment, logistics and regulatory challenges which prevents cell and gene therapies being widely used.

A unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges is presented at the 2nd Annual Cell Therapy Bioprocessing Conference, taking place at Boston-USA on 25th & 26th June 2020.

Key Highlights

Why Attend

Who Should Attend:

From Therapeutics and Pharmaceuticals, Cell & Gene therapy-based companies:

Engineers/ Scientists/ Researchers/ Project leaders in:

Agenda:

Day 1: Thursday June 25th

CELL CULTURE TO CELL THERAPY

CELL THERAPY BIOPROCESSING AND DEVELOPMENT

PROCESS MONITORING & QUALITY CONTROL

Day 2: Friday June 26th

LOGISTICS, REGULATORY & INVESTMENT

Speakers:

For more information about this conference visit https://www.researchandmarkets.com/r/z4ezsr

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/two-day-conference-on-cell-therapy-bioprocessing-boston-ma-united-states---june-25-26-2020---gain-insight-into-the-latest-advancements-and-opportunities-in-the-cell-gene-therapy-manufacturing-area-300998633.html

SOURCE Research and Markets

The rest is here:
Two Day Conference on Cell Therapy Bioprocessing (Boston, MA, United States - June 25-26, 2020) - Gain Insight into the Latest Advancements and...

Global Viral Inactivation Market Analysis 2016 to 2026 – Market Expected to Reach $1,209.17 Million by 2026 – ResearchAndMarkets.com – Yahoo Finance

The "Global Viral Inactivation Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Viral Inactivation market is expected to reach $1,209.17 million by 2026 growing at a CAGR of 14.2% from 2018 to 2026.

Factors such as increasing government support for pharmaceutical and biotechnology industries, an increase in the number of drug launches & approvals and rising investment in the life sciences sector are driving the market growth. Though, high cost of biologics and biosimilar products development & manufacturing restrain the market growth.

Based on the product, Kits and reagents are expected to have a lucrative growth during the forecast period due to their continuous usage by pharmaceutical and biopharmaceutical companies. With an increase in the number of pharmaceutical and biopharmaceutical companies and the rise in R&D spending for the purpose of new drug development, the usage of kits and reagents has increased tremendously.

Key Questions Answered in this Report:

The key vendors mentioned are Merck KGAA, Cerus Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Texcell, Inc., Parker Hannifin Corporation, Sanofi SA, SGS SA, Invitrogen Corp., General Electric Co., Rad Source Technologies, Qiagen NV, ZeptoMetrix Corp., MockV Solutions, Vironova AB, Viral Inactivated Plasma Systems SA, and BioReliance.

Key Questions Answered in this Report:

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Viral Inactivation Market, By Product

5.1 Introduction

5.2 Services

5.3 Viral Inactivation Systems and Accessories

5.4 Kits and Reagents

6 Global Viral Inactivation Market, By Method

6.1 Introduction

6.2 Pasteurization

6.3 Solvent Detergent Method

6.4 Other Methods

7 Global Viral Inactivation Market, By Application

7.1 Introduction

7.2 Blood and Blood Products

7.3 Tissues and Tissue Products

7.4 Vaccines and Therapeutics

7.5 Stem Cell Products

7.6 Cellular and Gene Therapy Products

8 Global Viral Inactivation Market, By End User

8.1 Introduction

8.2 Pharmaceutical and Biotechnology Companies

8.3 Academic Research Institutes

8.4 Contract Research Organizations

8.5 Blood Banks and Hospitals

9 Global Viral Inactivation Market, By Geography

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 South America

9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape

11.1 Merck KGAA

11.2 Cerus Corporation

11.3 Thermo Fisher Scientific Inc.

11.4 Sartorius AG

11.5 Danaher Corporation

11.6 Texcell, Inc.

11.7 Parker Hannifin Corporation

11.8 Sanofi SA

11.9 SGS SA

11.10 Invitrogen Corp.

11.11 General Electric Co.

11.12 Rad Source Technologies

11.13 Qiagen NV

11.14 ZeptoMetrix Corp.

11.15 MockV Solutions

11.16 Vironova AB

11.17 Viral Inactivated Plasma Systems SA

11.18 BioReliance

For more information about this report visit https://www.researchandmarkets.com/r/m0wcqb

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005900/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Follow this link:
Global Viral Inactivation Market Analysis 2016 to 2026 - Market Expected to Reach $1,209.17 Million by 2026 - ResearchAndMarkets.com - Yahoo Finance

Biologics Safety Testing Market Will Be Hit $ 4.8 Billion By 2026 – Story of Future

The global Biologics Safety Testing Market is anticipated to grow at a constant CAGR around 11.7% from 2019 to 2026 and the market value reach around US$ 4.8 billion by 2026.

According to a new report by Acumen Research and Consulting, Recently published report titled Biologics Safety Testing Market Global Industry Analysis, Market Size, Opportunities and Forecast, 2019-2026. This report also covers details of market size, growth spectrum, and the competitive scenario of the Biologics Safety Testing Market in the forecast era.

Recent global market survey Biologics Safety Testing Market involves various industry organizations from different geographies to generate a report of more than 100 pages. The study is an optimal combination of quality and quantitative data which illustrates major market trends, challenges facing by industry and company, as well as gap analysis and new opportunities with trends on this market. The research links historical data for 2015-2018 and forecasts up to 2026. The objective of this research is to present an application; type and geographical region evaluation of the worldwide Biologics Safety Testing Market Regions include North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

Click To Get>>>FREE SAMPLE PDF (Including Full TOC, Table & Figures)

Biologics Safety Testing Market (By Product Type: Kits & Reagents, Instruments; By Application: Blood and Blood-related Products Testing, Vaccine and Therapeutics Development, Cellular and Gene Therapy, Tissue and Tissue-related Products Testing, Stem Cell Research; By Test Type: Endotoxin Tests, Sterility Tests, Cell Line Authentication and Characterization Tests, Residual Host Contamination Detection Tests, Adventitious Agent Detection Tests, Bioburden tests, Other) Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 2026

The research is also aimed at delivering the recent market intelligence and helping decision makers make sound investment evaluations, as well as defining and analysing changing trends and key drivers, challenges & opportunities. We have also implemented significant company rivals who penetrate the global Biologics Safety Testing Market with major strategies and competitive landscape to evaluate the situation of players currently. The study also identifies the qualitative effect on market segmentation and geographical regions of distinct market variables. Thus, the research builds the attractiveness of each important segment over the forecast period.

This research includes a thorough 360-degree analysis on this market, which provides insight into possibilities and difficulties for the stakeholders. It monitors the worldwide Biologics Safety Testing Market in developed economies and provides detailed comment and precise quantitative insight. The research also involves incisive competitive landscape analyses and offers important market players suggestions on effective imperatives and strategies.

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2018. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2019 to 2026. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

Key Players & Strategies

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Biologics Safety Testing Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues.

Some major players in the Intelligent Intravenous Infusion Pumps Market include Charles River Laboratories, SGS SA, Lonza Group LTD, Merck KGaA, and WuXi Apptec, Thermo Fisher Scientific Inc., Sartorius AG, Cytovance Biologics, Inc., Pace Analytical Services Inc., Eurofins Scientific Se, Avance Biosciences Inc., Source Bioscience, and Toxikon Corporation among others.

Market Segmentation

Market By Product Type

Market By Application

Market By Test Type

Market By Geography

Key Takeaways:

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com| +1 407 915 4157

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW1.1. Definition and Scope1.1.1. Definition of Biologics Safety Testing1.1.2. Market Segmentation1.1.3. List of Abbreviations1.2. Summary1.2.1. Market Snapshot1.2.2. Biologics Safety Testing Market By Application1.2.2.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Application (2015-2026)1.2.2.2. Global Biologics Safety Testing Market Revenue Share By Application in 20171.2.2.3. Vaccine and Therapeutics Development1.2.2.4. Blood and Blood-related Products Testing1.2.2.5. Cellular and Gene Therapy1.2.2.6. Tissue and Tissue-related Products Testing1.2.2.7. Stem Cell Research1.2.3. Biologics Safety Testing Market By Product Type1.2.3.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Product Type (2015-2026)1.2.3.2. Global Biologics Safety Testing Market Revenue Share By Product Type in 20171.2.3.3. Kits & Reagents1.2.3.4. Instruments1.2.4. Biologics Safety Testing Market By Test Type1.2.4.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison By Test Type (2015-2026)1.2.4.2. Global Biologics Safety Testing Market Revenue Share By Test Type in 20171.2.4.3. Sterility Tests1.2.4.4. Endotoxin Tests1.2.4.5. Cell Line Authentication and Characterization Tests1.2.4.6. Residual Host Contamination Detection Tests1.2.4.7. Adventitious Agent Detection Tests1.2.4.8. Bioburden tests1.2.4.9. Others1.2.5. Biologics Safety Testing Market By Geography1.2.5.1. Global Biologics Safety Testing Market Revenue and Growth Rate Comparison by Geography (2015-2026)1.2.5.2. North America Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.3. Europe Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.4. Asia-Pacific Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.5. Latin America Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)1.2.5.6. Middle East and Africa (MEA) Biologics Safety Testing Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS2.1. Market Drivers2.2. Restraints and Challenges2.3. Growth Opportunities2.4. Porters Five Forces Analysis2.4.1. Bargaining Power of Suppliers2.4.2. Bargaining Power of Buyers2.4.3. Threat of Substitute2.4.4. Threat of New Entrants2.4.5. Degree of Competition2.5. Value Chain Analysis2.6. Cost Structure Analysis2.6.1. Raw Material and Suppliers2.6.2. Manufacturing Process Analysis2.7. Regulatory Compliance2.8. Competitive Landscape, 20172.8.1. Player Positioning Analysis2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS3.1. Capacity and Commercial Production Date of Global Biologics Safety Testing Major Manufacturers in 20173.2. Manufacturing Plants Distribution of Global Biologics Safety Testing Major Manufacturers in 20173.3. R&D Status and Technology Source of Global Biologics Safety Testing Major Manufacturers in 20173.4. Raw Materials Sources Analysis of Global Biologics Safety Testing Major Manufacturers in 2017

CHAPTER 4. BIOLOGICS SAFETY TESTING MARKET BY APPLICATION4.1. Global Biologics Safety Testing Revenue By Application4.2. Vaccine and Therapeutics Development4.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.3. Blood and Blood-related Products Testing4.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.4. Cellular and Gene Therapy4.4.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.4.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.5. Tissue and Tissue-related Products Testing4.5.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.5.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)4.6. Stem Cell Research4.6.1. Market Revenue and Growth Rate, 2015 2026 ($Million)4.6.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 5. BIOLOGICS SAFETY TESTING MARKET BY PRODUCT TYPE5.1. Global Biologics Safety Testing Revenue By Product Type5.2. Kits & Reagents5.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)5.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)5.3. Instruments5.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)5.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 6. BIOLOGICS SAFETY TESTING MARKET BY TEST TYPE6.1. Global Biologics Safety Testing Revenue By Test Type6.2. Sterility Tests6.2.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.2.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.3. Endotoxin Tests6.3.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.3.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.4. Cell Line Authentication and Characterization Tests6.4.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.4.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.5. Residual Host Contamination Detection Tests6.5.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.5.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.6. Adventitious Agent Detection Tests6.6.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.6.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.7. Bioburden tests6.7.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.7.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)6.8. Others6.8.1. Market Revenue and Growth Rate, 2015 2026 ($Million)6.8.2. Market Revenue and Forecast, By Region, 2015 2026 ($Million)

CHAPTER 7. NORTH AMERICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY7.1. North America Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)7.2. North America Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)7.3. U.S.7.3.1. U.S. Biologics Safety Testing Market Revenue and Forecast By Application, 2015 2026 ($Million)7.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)7.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)7.4. Canada7.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)7.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)7.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 8. EUROPE BIOLOGICS SAFETY TESTING MARKET BY COUNTRY8.1. Europe Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)8.2. Europe Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)8.3. UK8.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.4. Germany8.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.5. France8.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.6. Spain8.6.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.6.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.6.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)8.7. Rest of Europe8.7.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)8.7.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)8.7.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC BIOLOGICS SAFETY TESTING MARKET BY COUNTRY9.1. Asia-Pacific Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)9.2. Asia-Pacific Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)9.3. China9.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.4. Japan9.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.5. India9.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.6. Australia9.6.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.6.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.6.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.7. South Korea9.7.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.7.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.7.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)9.8. Rest of Asia-Pacific9.8.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)9.8.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)9.8.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 10. LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY10.1. Latin America Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)10.2. Latin America Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)10.3. Brazil10.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)10.4. Mexico10.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)10.5. Rest of Latin America10.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)10.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)10.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 11. MIDDLE EAST & AFRICA BIOLOGICS SAFETY TESTING MARKET BY COUNTRY11.1. Middle East & Africa Biologics Safety Testing Market Revenue and Growth Rate, 2015 2026 ($Million)11.2. Middle East & Africa Biologics Safety Testing Market Revenue Share Comparison, 2015 & 2026 (%)11.3. GCC11.3.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.3.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.3.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)11.4. Saudi Africa11.4.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.4.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.4.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)11.5. Rest of Middle East & Africa11.5.1. Market Revenue and Forecast By Application, 2015 2026 ($Million)11.5.2. Market Revenue and Forecast By Product Type, 2015 2026 ($Million)11.5.3. Market Revenue and Forecast By Test Type, 2015 2026 ($Million)

CHAPTER 12. COMPANY PROFILE12.1. Charles River Laboratories12.1.1. Company Snapshot12.1.2. Overview12.1.3. Financial Overview12.1.4. Product Portfolio12.1.5. Key Developments12.1.6. Strategies12.2. SGS SA12.2.1. Company Snapshot12.2.2. Overview12.2.3. Financial Overview12.2.4. Product Portfolio12.2.5. Key Developments12.2.6. Strategies12.3. Lonza Group LTD12.3.1. Company Snapshot12.3.2. Overview12.3.3. Financial Overview12.3.4. Product Portfolio12.3.5. Key Developments12.3.6. Strategies12.4. Merck KGaA12.4.1. Company Snapshot12.4.2. Overview12.4.3. Financial Overview12.4.4. Product Portfolio12.4.5. Key Developments12.4.6. Strategies12.5. WuXi Apptec12.5.1. Company Snapshot12.5.2. Overview12.5.3. Financial Overview12.5.4. Product Portfolio12.5.5. Key Developments12.5.6. Strategies12.6. Thermo Fisher Scientific Inc.12.6.1. Company Snapshot12.6.2. Overview12.6.3. Financial Overview12.6.4. Product Portfolio12.6.5. Key Developments12.6.6. Strategies12.7. Sartorius AG12.7.1. Company Snapshot12.7.2. Overview12.7.3. Financial Overview12.7.4. Product Portfolio12.7.5. Key Developments12.7.6. Strategies12.8. Cytovance Biologics, Inc.12.8.1. Company Snapshot12.8.2. Overview12.8.3. Financial Overview12.8.4. Product Portfolio12.8.5. Key Developments12.8.6. Strategies12.9. Pace Analytical Services Inc.12.9.1. Company Snapshot12.9.2. Overview12.9.3. Financial Overview12.9.4. Product Portfolio12.9.5. Key Developments12.9.6. Strategies12.10. Eurofins Scientific Se12.10.1. Company Snapshot12.10.2. Overview12.10.3. Financial Overview12.10.4. Product Portfolio12.10.5. Key Developments12.10.6. Strategies12.11. Avance Biosciences Inc.12.11.1. Company Snapshot12.11.2. Overview12.11.3. Financial Overview12.11.4. Product Portfolio12.11.5. Key Developments12.11.6. Strategies12.12. Source Bioscience12.12.1. Company Snapshot12.12.2. Overview12.12.3. Financial Overview12.12.4. Product Portfolio12.12.5. Key Developments12.12.6. Strategies12.13. Toxikon Corporation12.13.1. Company Snapshot12.13.2. Overview12.13.3. Financial Overview12.13.4. Product Portfolio12.13.5. Key Developments12.13.6. Strategies12.14. Others12.14.1. Company Snapshot12.14.2. Overview12.14.3. Financial Overview12.14.4. Product Portfolio12.14.5. Key Developments12.14.6. Strategies

CHAPTER 13. RESEARCH APPROACH13.1. Research Methodology13.1.1. Initial Data Search13.1.2. Secondary Research13.1.3. Primary Research13.2. Assumptions and Scope

Buy this Premium Research Report@https://www.acumenresearchandconsulting.com/buy-now/0/1656

The report is readily available and can be dispatched immediately after payment confirmation.

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Saurabh S.Phone: +14079154157 | +14089009135Email: sales@acumenresearchandconsulting.comWebsite:https://www.acumenresearchandconsulting.comFollow Us:LinkedIN |Twitter

See more here:
Biologics Safety Testing Market Will Be Hit $ 4.8 Billion By 2026 - Story of Future

Dementia Live and ‘Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients’ seminars – Trumbull Times

Published 7:30am EST, Monday, February 3, 2020

Bridges by EPOCH at Trumbull, a memory care assisted living community, located at 2415 Reservoir Ave., will host the following complimentary events in February. Call 203-935-8530 to RSVP.

Dementia Live Experience Thursday, Feb. 6, from 4 to 8 p.m. Presented by Right at Home, Caregivers are invited to reserve a time slot to step inside the body and mind of dementia. This powerful virtual experience will allow caregivers to see, hear and feel what life is like for someone living with dementia. Caregivers may bring their loved ones with memory loss to enjoy an activity with Bridges residents during this seminar. Refreshments will be served.

Caregiver Support Group Wednesday, Feb. 19, at 5:30 p.m. Caregivers are invited to trade tips, socialize with others on a similar journey and receive expert advice from dementia care professionals who understand their challenges and concerns. Dinner will be served. Caregivers may bring their loved ones with memory loss to dine with Bridges residents while they attend the group.

Dine and Discover Stem Cell Therapy for Stroke and Traumatic Brain Injury (TBI) Patients: Thursday, Feb. 20, at 5 p.m.; With Guest Speaker Dr. Peter McAllister, co-founder and Chief Medical Officer, New England Institute for Clinical Research. Stroke and traumatic brain injury strike millions of people each year. Dr. McAllister will discuss the various treatment options for the long-term effects of these conditions, including weakness, spasticity, language and cognitive difficulties and pain. He'll also discuss new research on stem cell therapy that could help restore function for stroke and TBI patients. Caregivers may bring their loved ones with memory loss to enjoy a meal and an activity with Bridges by EPOCH residents during this seminar. Dinner will be served.

See the original post:
Dementia Live and 'Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients' seminars - Trumbull Times

Global Stem Cell and Primary Cell Culture Medium Market Technology, Development, Trends and Forecasts to 2026 – Instant Tech News

Report of Global Stem Cell and Primary Cell Culture Medium Market is generated by Orbis Research providing the comprehensive study of the industry. Orbis Research is considering the year 2019 as a base year and forecast period for predicting the growth of the market is 2020-2026. Orbis Research is delivering the reports of market research on several categories by an organized method of judging the client, examining market supply, researching, struggle and demand, accompanied by integrating the feedback of the client.

Request a Sample Copy of this [emailprotected]https://www.orbispharmareports.com/sample-request/5800

The Stem Cell and Primary Cell Culture Medium report is a detailed study about top manufacturers, their revenue share, data, deals income, purchaser volume and deal volume. The report, at first, introduces markets classifications, applications definitions, and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. It exhibits the records that Stem Cell and Primary Cell Culture Medium has set in past and is expected to set in the forthcoming years, despite of the altering market trends and fluctuations.

The market reports are developed on the basis of specific parameters. The report dedicatedly cater professional solutions for corporate strategic decision-making. It adopts global scientific management system, catering top-notch consulting services to clients. Delving into the report, meticulous market revenues and shares growth patterns, analysis of market trends, and the value and volume of the market is mentioned.

Key Players listed in the report are:

MerckSTEMCELL TechnologiesIrvinesciCell Applications, IncBiological IndustriesMiltenyi BiotecSwiss Medica ClinicPromocellCreative BiolabsLifeline Cell TechnologyScienCell Research LaboratoriesOsiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Global Stem Cell and Primary Cell Culture Medium Sales Growth Rate Comparison by Type

Liquid MediaPowder Media

Stem Cell and Primary Cell Culture Medium Sales Comparison by Application:

Biopharmaceutical ManufacturingTissue Engineering & Regenerative MedicineGene TherapyOther

The market report follows amalgamation of methodological research and structured methodology. These methods probe into markets with help of thorough research and analysis. In general, the research is defined as extracted information from various sources such as vendors, products, research papers, manufacturers and more. The analysis part is inclusive of quantitative and qualitative analysis of markets such as market forecasts, market segmentations, business models, and many more. Each market study offers equal importance to its prominent manufacturers who operate the market. For budding entrepreneurs, investors and organizations, the detailed analysis of manufacturers is essential. To retain in the competitive landscape, manufacturers also require detailed information of other manufacturers business strategies, models, revenue growth and all other crucial information.

Moreover, the report describes the segmentation of market based on various parameters and attributes. Market segmentation is based on geography, demography, types, product, etc. This leads to easy understanding of customers behavior and demand towards a specific market or product. The key aspect covered in market segmentation is regional study. With help of regional analysis, marketers and investors can get clear idea of business opportunities, potential revenue generation and upcoming opportunities residing in the coming years. For a global business expansion or a regional business establishment, this information have immense effect.

To make an enquiry on [emailprotected] https://www.orbispharmareports.com/enquiry-before-buying/5800

Furthermore, the Stem Cell and Primary Cell Culture Medium report highlights the North American and European region. As these regions leads the most market or the most prominent ones, have extreme importance when setting up a business or expanding it. The report has given description about these regions developing trends, marketing channels which are mostly preferred, investment feasibility for long-term investments and environmental analysis. It is also consists capacity, product price, profit, supply, demand, production and market growth rate and forecast etc. The report also comprise other developing economies market demand and the causes which triggered this demand. It also covers detailed information of market price and size of other key regions which includes South America, Asia, Europe and Middle East.

The Stem Cell and Primary Cell Culture Medium report covers all the potential aspects of a market and provides a brief conclusion to its readers.

Table of Contents

Chapter One: Stem Cell and Primary Cell Culture Medium Market Overview

1.1 Product Overview and Scope of Stem Cell and Primary Cell Culture Medium

1.2 Stem Cell and Primary Cell Culture Medium Segment by Type

1.2.1 Global Stem Cell and Primary Cell Culture Medium Production Growth Rate Comparison by Type 2020 VS 2026

1.2.2 Gas Stem Cell and Primary Cell Culture Medium

1.2.3 Electric Stem Cell and Primary Cell Culture Medium

1.3 Stem Cell and Primary Cell Culture Medium Segment by Application

1.3.1 Stem Cell and Primary Cell Culture Medium Consumption Comparison by Application: 2020 VS 2026

1.3.2 Quick Service Restaurants (QSR)

1.3.3 Full Service Restaurant/Main Line Dining

1.3.4 Retail Outlets

1.3.5 Others

1.4 Global Stem Cell and Primary Cell Culture Medium Market by Region

1.4.1 Global Stem Cell and Primary Cell Culture Medium Market Size Estimates and Forecasts by Region: 2020 VS 2026

1.4.2 North America Estimates and Forecasts (2015-2026)

1.4.3 Europe Estimates and Forecasts (2015-2026)

1.4.4 China Estimates and Forecasts (2015-2026)

1.4.5 Japan Estimates and Forecasts (2015-2026)

1.5 Global Stem Cell and Primary Cell Culture Medium Growth Prospects

1.5.1 Global Stem Cell and Primary Cell Culture Medium Revenue Estimates and Forecasts (2015-2026)

1.5.2 Global Stem Cell and Primary Cell Culture Medium Production Capacity Estimates and Forecasts (2015-2026)

1.5.3 Global Stem Cell and Primary Cell Culture Medium Production Estimates and Forecasts (2015-2026)

Browse full sample [emailprotected]http://www.orbispharmareports.com/2020-2026-global-stem-cell-and-primary-cell-culture-medium-market-in-depth-research-report/

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Originally posted here:
Global Stem Cell and Primary Cell Culture Medium Market Technology, Development, Trends and Forecasts to 2026 - Instant Tech News

THE MENA summit to explore innovation in the liberal arts – Times Higher Education (THE)

The value of a liberal arts education has become a pivotal discussion within the global higher education sector over the last decade. No longer confined to the hallowed halls of ivy-covered American colleges, this multidisciplinary approach, which focuses on developing creative thinking skills, has begun to transform the curricula of institutions worldwide.

To examine this further, the Times Higher Education 2020 MENA Summit, taking place at NYU Abu Dhabi on 10-12 March, will explore the benefits and challenges of broadening the liberal arts educational model across Middle Eastern and North African countries.

Fostering discussions on how to prepare students for a variety of career paths after graduation is high on the list of the summits objectives. Hoda Mostafa, director of the Center for Learning and Teaching at the American University in Cairo, will share useful practices to facilitate the leap between an interdisciplinary education and careers both in and out of academia.

Wasif Rizv,founding president of Habib University, Pakistans first liberal arts and science institution, will provide an instructional model from south-east Asia to demonstrate how a liberal arts education can develop talent to meet the demands of a global workforce.

Another key focus will be enhancing the research culture in countries where talent attraction has faced challenges. Rana Dajani, associate professor at Hashemite University, who established stem cell research ethics law in Jordan, will debate with other panellists which tools are needed to support the next generation of researchers in the MENA region.

Safwan Masri, the current vice-president for Global Centers and Global Development at Columbia University, who has written extensively on the role of Tunisia in the Arab Spring, will deliver the summits closing keynote, underlining the power of research and knowledge transfer in the region to ultimately promote a greater cultural understanding and bridge political boundaries.

The summit will include an exclusive THE rankings masterclass that will dissect the methodology behind the World University Rankings, giving an analysis of the MENA regions successes and future opportunities. Additionally, delegates will enjoy a deep-dive into THEs new University Impact Rankings, which are based on universities successes in working towards the United Nations Sustainable Development Goals.

John Gill, editor of THE, said: We are at a crucial moment for the world on numerous fronts from how to respond to global threats such as climate change, to how to navigate a path to greater understanding and collaboration. Higher education and research will play crucial roles in finding the answers.

At this summit, we will discuss the role of liberal arts education, at a time of debate about how best to prepare students for the new economy, and how to support societies in transition. We will consider how a global perspective can transform the impact of education, and address the interplay between education and research in the MENA region. These topics touch on every aspect of what universities do, as institutions that educate, create new knowledge, and drive economic and social progress, so we are delighted to have such a diverse programme of speakers, and to be meeting at NYU Abu Dhabi, itself a great example of innovation.

The Times Higher Education 2020 MENA Universities Summit will take place 10-12 March at NYU Abu Dhabi. Find out more.

Link:
THE MENA summit to explore innovation in the liberal arts - Times Higher Education (THE)

Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies – WhaTech…

Exosome Diagnostics Market Report analysis including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis for upcoming years.

ReportsnReports added a new report on The Exosome Diagnostics Market Technologies report delivers the clean elaborated structure of the Report comprising each and every business related information of the market at a global level. The complete range of information related to the Exosome Diagnostics Market Technologies is obtained through various sources and this obtained the bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade based study regarding the Exosome Diagnostics Market Technologies.

Download a Free PDF Sample of Exosome Diagnostics Market Technologies Research Report at:

http://www.reportsnreports.com/contactme=1781607

Top Companies mentioned in this report are Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell Medicine Ltd, Tavec Inc, Codiak Biosciences Inc, Therapeutic Solutions International Inc, ArunA Biomedical Inc, Ciloa 85.

This latest report is on Exosome Diagnostics Market Technologies which explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy.

Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intracellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biological vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

Reasons to buy this Report:

Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector, Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies, Identify trends in interventional and observational clinical trials relevant to exosomes.

Get this Report @ http://www.reportsnreports.com/purchasme=1781607

Scope of this Report:

What are the features of the exosome lifecycle?,How are therapeutic exosomes prepared?,How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?,Which companies are investing in exosome technologies?,How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Table of contents for Exosome Diagnostics Market Technologies:

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Exosomes in Healthcare 8

2.1 Overview of Exosomes 8

2.2 Drug Delivery Systems 9

2.2.1 Modified Release Drug Delivery Systems 9

2.2.2 Targeted Drug Delivery Systems 10

2.2.3 Liposomes 12

2.2.4 Viruses 14

2.2.5 Exosomes 17

2.3 The Exosome Lifecycle 18

2.4 Exosomes in Biology 18

2.5 Exosomes in Medicine 19

2.5.1 Biomarkers 19

2.5.2 Vaccines 20

2.6 Exosomes as a Therapeutic Target 20

2.7 Exosomes as Drug Delivery Vehicles 21

2.8 Therapeutic Preparation of Exosomes 21

2.8.1 Isolation and Purification 22

2.8.2 Drug Loading 22

2.8.3 Characterization 23

2.8.4 Bioengineering 23

2.8.5 Biodistribution and In Vivo Studies 23

2.8.6 Advantages of Exosome Therapies 24

2.8.7 Disadvantages of Exosome Therapies 24

2.9 Exosomes in Therapeutic Research 25

2.9.1 Exosome Gene Therapies 25

2.9.2 Exosome in Stem Cell Therapy 26

2.10 Exosomes in Oncology 27

2.10.1 Immunotherapy 27

2.10.2 Gene Therapy 28

2.10.3 Drug Delivery 29

2.10.4 Biomarkers 30

2.11 Exosomes in CNS Disease 30

2.11.1 Tackling the Blood-Brain Barrier 30

2.11.2 Exosomes in CNS Drug Delivery 31

2.11.3 Gene Therapy 32

2.12 Exosomes in Other Diseases 33

2.12.1 Cardiovascular Disease 33

2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

3.1 Overview 36

3.2 Exosome Pipeline by Stage of Development and Molecule Type 36

3.3 Pipeline by Molecular Target 37

3.4 Pipeline by Therapy Area and Indication 38

3.5 Pipeline Product Profiles 38

3.5.1 AB-126 - ArunA Biomedical Inc. 38

3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39

3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39

3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39

3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39

3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39

3.5.7 Biologics for Prostate Cancer - Cells for Cells 40

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40

3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41

3.5.10 CIL-15001 and CIL-15002 - Ciloa 42

3.5.11 ExoPr0 - ReNeuron Group Plc 42

3.5.12 MVAX-001 - MolecuVax Inc. 43

3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44

3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44

3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

4.1 Interventional Clinical Trials 48

4.1.1 Clinical Trials by Therapy Type 48

4.1.2 Clinical Trials by Therapy Area 49

4.1.3 Clinical Trials by Stage of Development 50

4.1.4 Clinical Trials by Start Date and Status 50

4.2 Observational Clinical Trials 51

4.2.1 Clinical Trials by Therapy Type 51

4.2.2 Clinical Trials by Therapy Area 51

4.2.3 Clinical Trials by Stage of Development 52

4.2.4 Clinical Trials by Start Date and Status 53

4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

5.1 Company Profiles 67

5.1.1 Capricor Therapeutics Inc. 67

5.1.2 Evox Therapeutics Ltd 72

5.1.3 ReNeuron Group Plc 73

5.1.4 Stem Cell Medicine Ltd 77

5.1.5 Tavec Inc. 78

5.1.6 Codiak Biosciences Inc. 80

Read more here:
Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies - WhaTech...

Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Stem Cell Banking - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global market for Stem Cell Banking is projected to reach US$9.9 billion by 2025, driven by their growing importance in medicine given their potential to regenerate and repair damaged tissue.

Stem cells are defined as cells with the potential to differentiate and develop into different types of cells. Different accessible sources of stem cells include embryonic stem cells, fetal stem cells, peripheral blood stem cells, umbilical cord stem cells, mesenchymal stem cells (bmMSCs) and induced pluripotent stem cells. Benefits of stem cells include ability to reverse diseases like Parkinsons by growing new, healthy and functioning brain cells; heal and regenerate tissues and muscles damaged by heart attack; address genetic defects by introducing normal cells; reduce mortality among patients awaiting donor organs for transplant by regenerating healthy cells and tissues as an alternative to donated organs. While currently valuable in bone marrow transplantation, stem cell therapy holds huge potential in treating a host of common chronic diseases such as diabetes, heart disease (myocardial infarction), Parkinsons disease, spinal cord injury, arthritis, and amyotrophic lateral sclerosis. The technology has the potential to revolutionize public health.

The growing interest in regenerative medicine which involves replacing, engineering or regenerating human cells, tissues or organs, will push up the role of stem cells. Developments in stem cells bioprocessing are important and will be key factor that will influence and help regenerative medicine research move into real-world clinical use. The impact of regenerative medicine on healthcare will be comparable to the impact of antibiotics, vaccines, and monoclonal antibodies in current clinical care. With global regenerative medicine market poised to reach over US$45 billion 2025, demand for stem cells will witness robust growth.

Another emerging application area for stem cells is in drug testing in the pharmaceutical field. New drugs in development can be safely, accurately, and effectively be tested on stem cells before commencing tests on animal and human models. Among the various types of stem cells, umbilical cord stem cells are growing in popularity as they are easy and safe to extract. After birth blood from the umbilical cord is extracted without posing risk either to the mother or the child. As compared to embryonic and fetal stem cells which are saddled with safety and ethical issues, umbilical cord is recovered postnatally and is today an inexpensive and valuable source of multipotent stem cells. Until now discarded as waste material, umbilical cord blood is today acknowledged as a valuable source of blood stem cells. The huge gap between newborns and available cord blood banks reveals huge untapped opportunity for developing and establishing a more effective banking system for making this type of stem cells viable for commercial scale production and supply. Umbilical cord and placenta contain haematopoietic blood stem cells (HSCs). These are the only cells capable of producing immune system cells (red cells, white cells and platelet).

HSCs are valuable in the treatment of blood diseases and successful bone marrow transplants. Also, unlike bone marrow stem cells, umbilical cord blood has the advantage of having 'off-the-shelf' uses as it requires no human leukocyte antigen (HLA) tissue matching. Developments in stem cell preservation will remain crucial for successful stem cell banking. Among the preservation technologies, cryopreservation remains popular. Development of additives for protecting cells from the stresses of freezing and thawing will also be important for the future of the market. The United States and Europe represent large markets worldwide with a combined share of 60.5% of the market. China ranks as the fastest growing market with a CAGR of 10.8% over the analysis period supported by the large and growing network of umbilical cord blood banks in the country. The Chinese government has, over the years, systematically nurtured the growth of umbilical cord blood (UCB) banks under the 'Developmental and Reproductive Research Initiation' program launched in 2008. Several hybrid public-private partnerships and favorable governmental licensing policies today are responsible for the current growth in this market.

Companies Mentioned

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

REST OF EUROPE

ASIA-PACIFIC

REST OF WORLD

IV. COMPETITION

V. CURATED RESEARCH

For more information about this report visit https://www.researchandmarkets.com/r/9b2ra3

Read the original:
Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com - Business Wire

The Future of Antivenom May Involve Mini Lab-Grown Snake Glands – Smithsonian.com

For the first time, scientists have grown miniature, venom-producing glands in the lab using coral snake embryos, according to a news study published in the journal Cell. Why might researchers want to create artificial venom glands, you ask?

The project was initially aimed to establish proof-of-concept more than anything else. Three graduate students at the Hubrecht Institute in the Netherlands had wondered: If lab-grown organs could be made that acted like mouse and human tissues, would it work for other animals, like reptiles?

Luckily, they were working in molecular geneticist Hans Clevers lab. Clevers is a prominent expert in stem cell research who pioneered research on the lab-grown organ imitationscalled organoidsa decade ago. Since then, researchers have created miniature human kidneys, livers, and brains in petri dishes.

On Fridays, members of the Clevers Lab are allowed to work on unstructured projects. To put their question to the test, Clevers students Yorick Post, Jens Puschhof, and Joep Beumer, would need a source of reptilian stem cells. As it happened, one of the researchers knew a guy: a snake breeder who could supply them with fertilized eggs, as STAT News Andrew Joseph reports.

They started with the egg of a Cape coral snake, removing the embryos venom glands and placing them in a dish. Then, they followed nearly the same protocol as they did with human cells, giving the cells ample supply of growth-inducing chemicals and storing them at a comfortable temperatureabout 89 degrees Fahrenheit, about ten degrees lower than the temperature used for human cells.

Soon, the plates held one-millimeter-long white blobs producing dangerous venom. With the organoids alive and well, the researchers told Clevers what theyd done, Leslie Nemo at Discover reports. If theyd told him beforehand, he would have told them it probably wouldnt work, Clevers tells the Atlantics Ed Yong. The chemicals they used were designed for human stem cells, and very little was known about stem cells in snakes. Still, the researchers were able to grow organoids from nine species of snakes.

Its a breakthrough, University of Costa Rica snake venom toxicologist Jos Mara Gutirrez, who was not involved in the study, tells Erin Malsbury at Science magazine. This work opens the possibilities for studying the cellular biology of venom-secreting cells at a very fine level, which has not been possible in the past, Malsbury says.

By looking closely at the organoids, Clevers team gained new insight into how multiple kinds of cells work together to produce the specific mixture of toxins and proteins that results in fully-developed venom.

Venomous snake bites kill between 81,000 and 138,000 people every year, according to the World Health Organization, and cause three times as many amputations and disabilities. The antidote to a snakebite is an antivenom, but each of thousands of venomous snakes have a different biteeach requiring a unique treatment. Even snakes of the same species can produce a slightly different venoms if they live in different regions.

Right now, antivenoms are produced using much the same process as was invented in the 19th century: a live snake is milked for its venom, that venom is injected into a horse. Horses have been used for antivenom production for years because of their docile nature and big veins, as Douglas Main wrote for Popular Mechanics in 2016. They are first injected with adjuvant, which stimulates their immune system to produce enough antibodies to neutralize the venom. Then, researchers take a sample of their blood and separate the antivenom from other component of blood, like plasma, in a centrifuge.

Clevers now hopes to create a bank of dozensand eventually thousandsof organoids from dangerous snakes and other reptiles that could aid in the effort to manufacture effective antivenoms.

"We could just sample one tissue once, and we have a source of [that snakes] venom for eternity," Clevers tells Discover.

Clevers is working with the Dutch biologist Freek Vonk, who he calls the Dutch Steve Irwin, to get samples of the snake species he hopes to include in the venom gland biobank. (Vonk works at Naturalis Biodiversity Center in Leiden and also has some excellent Dutch science tunes available on Spotify.)

With venom from organoids more easily available, the hope is to skip the horse in the antitoxin-production process. Researchers could instead use the organoid-produced venom to test an array of molecules for neutralizing abilities.

It will be interesting to see how the cost of producing venom using this system compares to the cost of purchasing venom milked from live snakes, since cost of antivenom is a key impediment to its wider use in countries where snakebite is a huge issue, like India and Nigeria, as Bangor University molecular zoologist Anita Malhotra tells the Atlantic.

Antivenoms made from lab-grown venom glands are likely years away, but the organoids could also be a big step for studying toxin production in more detail than previously possible. With the cells isolated from the rest of the snake, researchers might be able to look at how they can produce toxic chemicals without damaging themselves, for example.

Clevers tells Discover, We do the most interesting work when we dont have a proposal and just try things.

Continued here:
The Future of Antivenom May Involve Mini Lab-Grown Snake Glands - Smithsonian.com